Annonce • May 20
Victrex plc Announces Stepping Down of David Thomas as Non-Executive Director, Effective May 18, 2026 Victrex PLC announces that David Thomas has informed the Board that he has stepped down as a Non-executive director of the Company with immediate effect on May 18, 2026, due to ill health. David Thomas was appointed as Non-executive director in 2018. Declared Dividend • May 13
First half dividend of UK£0.13 announced Shareholders will receive a dividend of UK£0.13. Ex-date: 28th May 2026 Payment date: 26th June 2026 Dividend yield will be 11%, which is higher than the industry average of 6.1%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. The dividend is also not covered by cash flows (106% cash payout ratio). The dividend has increased by an average of 2.4% per year over the past 10 years. However, payments have been volatile during that time. Reported Earnings • May 12
First half 2026 earnings released: UK£0.37 loss per share (vs UK£0.17 profit in 1H 2025) First half 2026 results: UK£0.37 loss per share (down from UK£0.17 profit in 1H 2025). Revenue: UK£147.1m (flat on 1H 2025). Net loss: UK£32.3m (down 313% from profit in 1H 2025). Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Chemicals industry in Germany. Annonce • May 12
Victrex plc Announces Interim Dividend for the Six Months Ended 31 March 2026, Payable on 26 June 2026 Victrex plc announced interim dividend for the six months ended 31 March 2026 of 13.42 pence per share will be paid on 26 June 2026 to shareholders on the register at the close of business on 29 May 2026. This dividend will be recognised in the period in which it is approved. New Risk • Apr 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 186% Cash payout ratio: 105% Minor Risks Share price has been volatile over the past 3 months (8.8% average weekly change). Large one-off items impacting financial results. Valuation Update With 7 Day Price Move • Mar 20
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to €5.85, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 14x in the Chemicals industry in Germany. Annonce • Feb 11
Victrex plc Announces Changes to Its Board and Committee Spirax Group plc announced the appointment of Maria Antoniou, Non-Executive Director and Chair of the Remuneration Committee, has been appointed as a Non-Executive Director of Victrex plc with effect from 1 September 2026. Victrex plc also announced the appointment of Peter Kiernan as non-executive director and David Thomas, non-executive director and Chair of the Audit Committee, will retire from the Board on 1 July 2026, and Peter will succeed David as Chair of the Audit Committee from that date. Peter Kiernan has significant experience in executive and non-executive roles. He had a 30 year career in investment banking with a focus on M&A and general corporate finance advice, including senior roles at S.G. Warburg/UBS, Goldman Sachs, Lazard and Hawkpoint Partners/Canaccord Genuity. He started his career at Peat, Marwick, Mitchell where he qualified as a Chartered Accountant. He holds an MA in Natural Sciences (Chemistry) from Cambridge University. Peter has held several advisory and non-executive positions. He currently holds senior advisory roles at Egon Zehnder and OMERS Private Equity (Europe). Prior non-executive roles include Tungsten Corporation, a public company where he was Audit Committee Chair and Senior Independent Director, Lifeways Group, a private equity owned business where he was Audit Committee Chair and Chair, and Business LDN where he was Chair of the Finance Committee. MariaAntoniou has extensive experience in both executive and non-executive roles within UK plc Boards. She is currently Chief Human Resources Officer at Morgan Advanced Materials plc and a non-executive director at FTSE 100 listed Spirax Group plc. Until last year she was a non-executive director of NATS (the National Air Traffic Service). Maria has a strong background in international industrial businesses, having worked in significant roles at Ford, Jaguar Land Rover and E.ON. Her experience spans across various sectors, including automotive, energy, and advanced materials, which gives her a comprehensive understanding of the challenges and opportunities within industries aligned to Victrex's end-markets. Annonce • Feb 06
Jakob Sigurdsson Steps Down as an Executive Director of Victrex Plc, Effective from February 6, 2026 Coats Group PLC announces that it has been notified that Jakob Sigurdsson, a Non-Executive Director of the Company, has on February 6, 2026, stepped down as an Executive Director of Victrex plc. Upcoming Dividend • Jan 22
Upcoming dividend of UK£0.46 per share Eligible shareholders must have bought the stock before 29 January 2026. Payment date: 27 February 2026. The company is paying out more than 100% of its earnings and cash flow. Trailing yield: 8.3%. Within top quartile of German dividend payers (4.5%). Higher than average of industry peers (4.4%). New Risk • Dec 05
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 27% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 186% Cash payout ratio: 105% Minor Risk Large one-off items impacting financial results. Reported Earnings • Dec 03
Full year 2025 earnings released: EPS: UK£0.32 (vs UK£0.20 in FY 2024) Full year 2025 results: EPS: UK£0.32 (up from UK£0.20 in FY 2024). Revenue: UK£292.7m (flat on FY 2024). Net income: UK£27.8m (up 62% from FY 2024). Profit margin: 9.5% (up from 5.9% in FY 2024). Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 2.5% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 46% per year but the company’s share price has only fallen by 29% per year, which means it has not declined as severely as earnings. Annonce • Oct 22
Victrex plc, Annual General Meeting, Feb 06, 2026 Victrex plc, Annual General Meeting, Feb 06, 2026. Board Change • Oct 08
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 1 highly experienced director. Independent Non-Executive Director Urmi Richardson was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Sep 02
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. No highly experienced directors. Independent Non-Executive Director Urmi Richardson was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Aug 02
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. No highly experienced directors. Independent Non-Executive Director Urmi Richardson was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Declared Dividend • May 26
First half dividend of UK£0.13 announced Shareholders will receive a dividend of UK£0.13. Ex-date: 29th May 2025 Payment date: 27th June 2025 Dividend yield will be 7.4%, which is higher than the industry average of 6.1%. Sustainability & Growth Dividend is not covered by earnings (175% earnings payout ratio). However, it is covered by cash flows (80% cash payout ratio). The dividend has increased by an average of 2.8% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 94% to bring the payout ratio under control. EPS is expected to grow by 99% over the next 3 years, which is sufficient to bring the dividend into a sustainable range. Annonce • Dec 06
Victrex plc, Annual General Meeting, Feb 07, 2025 Victrex plc, Annual General Meeting, Feb 07, 2025. Annonce • Dec 03
Victrex plc Proposes Final Dividend for the Fiscal Year 2025, Payable on 21 February 2025 Victrex plc at its AGM to be held on 7 February 2025, proposed final dividend at 46.14 pence per share (fiscal year 2024: 46.14 pence per share), with an Ex-dividend date: 23 January 2025, Record date: 24 January 2025 and Payment of final dividend: 21 February 2025. Annonce • Sep 18
Victrex plc Announces in Partnership with Maxx Orthopedics Inc, FDA Grants IDE Approval for Freedom Total Knee System with Invibio PEEK-OPTIMA Femoral Component as Staged Study Victrex plc announced that, in partnership with Maxx Orthopedics Inc, the U.S. Food and Drug Administration (FDA) has granted Investigational Device Exemption (IDE) approval for Freedom Total Knee System with Invibio PEEK-OPTIMA Femoral Component, as a staged study. The study, projected to be 120 patients at clinical sites in the US, will compare using the PEEK-OPTIMA Femoral Knee Component to a controlled registry of the same system using traditional metal femoral components. The US study will build on the existing clinical trial for PEEK Knee at sites in Belgium, India and Italy, which has been progressing strongly since the first implant in 2021, with no clinical intervention. A regulatory submission in India is also expected imminently, supporting the potential for a commercial PEEK Knee in the market in 2025. Annonce • Sep 06
Victrex plc to Report Fiscal Year 2024 Results on Dec 03, 2024 Victrex plc announced that they will report fiscal year 2024 results on Dec 03, 2024 Valuation Update With 7 Day Price Move • Aug 06
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to €12.50, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 12x in the Chemicals industry in Germany. Total loss to shareholders of 53% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €22.26 per share. Declared Dividend • May 23
First half dividend of UK£0.13 announced Shareholders will receive a dividend of UK£0.13. Ex-date: 30th May 2024 Payment date: 28th June 2024 Dividend yield will be 4.5%, which is lower than the industry average of 6.1%. Sustainability & Growth Dividend is not covered by earnings (169% earnings payout ratio) nor is it covered by cash flows (411% cash payout ratio). The dividend has increased by an average of 4.4% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 87% to bring the payout ratio under control. EPS is expected to grow by 141% over the next 3 years, which is sufficient to bring the dividend into a sustainable range. Annonce • May 15
Victrex plc Announces Interim Dividend , Payable on June 28, 2024 Victrex plc announced that an interim dividend of 13.42 pence per share (First half 2023: 13.42 pence) will be paid on 28 June 2024 to shareholders on the register at the close of business on 31 May 2024. This dividend will be recognised in the period in which it is approved. Annonce • Mar 15
Victrex plc Appoints Urmi Prasad Richardson as Non-Executive Director, Effective from May 1, 2024 Victrex plc announced that Urmi Prasad Richardson has been appointed as a non-executive director of the Board, effective from May 1, 2024. Urmi has a wealth of global experience in executive and non-executive roles over a 25 year period. She has a particular focus on science, medical and innovation based businesses. Urmi is currently President EMEA of Thermo Fisher Scientific, a world leader in serving science, with products which help accelerate life science research and improve patient health. Her executive career includes roles at The Linde Group, where she was Global Head of Healthcare, at Novartis and Foundation Medicine (a Roche company). She started her career with G.D. Searle (a Pfizer company) and has worked throughout Europe and the US. Urmi has extensive experience in strategy, business development and product commercialisation in Europe, Asia and North America. Urmi holds a number of advisory Board roles at unlisted organizations in the sectors of longevity, blockchain, and targeted therapy in oncology. Her previous non-executive roles include Linde Healthcare. Annonce • Feb 27
Victrex plc to Report First Half, 2024 Results on May 13, 2024 Victrex plc announced that they will report first half, 2024 results on May 13, 2024 Annonce • Feb 09
Victrex plc Provides Earnings Guidance for the First Half and Full Year of Fiscal Year 2024 Victrex plc provided earnings guidance for the first half and full year of fiscal year 2024. First half revenue is expected to be lower than the prior year period.The Group previously communicated that progress in revenue for fiscal year 2024. Annonce • Oct 14
Victrex Announces New Product Grade Launch, Victrex Pharmaceutical Contact (PC)101 (VICTREX PC101), Developed Exclusively for the Drug Delivery Device Market Victrex plc have launched a new product grade developed exclusively for Drug Delivery and Pharmaceutical Contact applications. VICTREX PC101™ meets the highest levels of Industry biocompatibility certification for USP Class VI and also meets industry standards such as USP 661 for use in non-implantable pharmaceutical contact applications. This material is available in granules and film and adds value to pharmaceutical production companies and drug delivery device manufacturers by providing access to assured materials for equipment or devices. This has the potential to save them cost, time and reduce risk, ultimately streamlining the commercialisation of their own products. VICTREX PC101™ is a PEEK-based material ideally suited to non-implantable Pharmaceutical contact and drug delivery applications for less than 24-hour tissue contact duration, whether they are production line equipment or primary packaging and end delivery devices. Victrex also offers unparalleled expertise, experience and support to customers, having been the first to commercialise the use of PEEK over 40 years ago. PEEK materials have properties meeting high levels of physical and chemical performance, ideal for applications requiring sterilisation, retention of dimensional stability, or chemical, electrical and temperature resistance. PEEK also meets high levels of mechanical performance, perfectly suited for high strength and miniature parts, wear, abrasion and fatigue exposure. It is also versatile for thermoplastic processing through moulding processes, milling or additive manufacturing. Victrex offer a unique perspective on this market as their medical business, Invibio, has over 20 years of proven clinical history in implantable medical PEEK devices. This insight and experience have enabled them to become a key player in the drug delivery device space over recent years. They are well placed to collaborate with OEMs, engineers and pharma manufacturing companies to support them from design, regulatory approval, manufacture and beyond. Annonce • Jul 07
Victrex plc to Report Q4, 2023 Results on Dec 04, 2023 Victrex plc announced that they will report Q4, 2023 results on Dec 04, 2023 Reported Earnings • Dec 07
Full year 2022 earnings released: EPS: UK£0.88 (vs UK£0.84 in FY 2021) Full year 2022 results: EPS: UK£0.88 (up from UK£0.84 in FY 2021). Revenue: UK£341.0m (up 11% from FY 2021). Net income: UK£76.2m (up 4.1% from FY 2021). Profit margin: 22% (down from 24% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 3.3% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to remain flat. Over the last 3 years on average, earnings per share has fallen by 7% per year whereas the company’s share price has fallen by 9% per year. Annonce • Dec 07
Victrex plc Proposes Final Dividend for Fiscal Year 2022 Victrex plc proposing a final dividend of 46.14 pence /share (FY 2021: 46.14 pence /share) for fiscal year 2022, giving total dividends for the year of 59.56 pence /share. The closing available cash balance of £66.0 million was below the threshold to pay a special dividend. Annonce • Dec 06
Victrex plc, Annual General Meeting, Feb 10, 2023 Victrex plc, Annual General Meeting, Feb 10, 2023. Annonce • Sep 15
Victrex plc to Report Fiscal Year 2022 Results on Dec 06, 2022 Victrex plc announced that they will report fiscal year 2022 results on Dec 06, 2022 Recent Insider Transactions • Feb 25
CEO & Executive Director recently bought €64k worth of stock On the 21st of February, Jakob Sigurdsson bought around 3k shares on-market at roughly €22.72 per share. This was the largest purchase by an insider in the last 3 months. Jakob has been a buyer over the last 12 months, purchasing a net total of €138k worth in shares. Upcoming Dividend • Jan 20
Upcoming dividend of UK£0.96 per share Eligible shareholders must have bought the stock before 27 January 2022. Payment date: 18 February 2022. Payout ratio is a comfortable 71% and this is well supported by cash flows. Trailing yield: 2.6%. Lower than top quartile of German dividend payers (3.4%). Lower than average of industry peers (3.5%). Reported Earnings • Jan 17
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Full year 2021 results: EPS: UK£0.84 (up from UK£0.63 in FY 2020). Revenue: UK£306.3m (up 15% from FY 2020). Net income: UK£73.2m (up 35% from FY 2020). Profit margin: 24% (up from 20% in FY 2020). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 1.0%. Over the next year, revenue is forecast to grow 3.7%, compared to a 4.9% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has remained flat, which means it is well ahead of earnings. Board Change • Nov 12
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 8 experienced directors. No highly experienced directors. Senior Independent Director Ros Rivaz was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Oct 14
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 8 experienced directors. No highly experienced directors. Senior Independent Director Ros Rivaz was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Sep 15
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 8 experienced directors. No highly experienced directors. Senior Independent Director Ros Rivaz was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Upcoming Dividend • May 27
Upcoming dividend of UK£0.13 per share Eligible shareholders must have bought the stock before 03 June 2021. Payment date: 30 June 2021. Trailing yield: 1.1%. Lower than top quartile of German dividend payers (3.2%). Lower than average of industry peers (3.6%). Reported Earnings • May 11
First half 2021 earnings released: EPS UK£0.47 (vs UK£0.48 in 1H 2020) The company reported a soft first half result with weaker earnings, although revenues and profit margins were flat. First half 2021 results: Revenue: UK£150.9m (flat on 1H 2020). Net income: UK£40.7m (down 1.0% from 1H 2020). Profit margin: 27% (in line with 1H 2020). Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings. Recent Insider Transactions • Mar 02
CEO & Executive Director recently bought €74k worth of stock On the 1st of March, Jakob Sigurdsson bought around 3k shares on-market at roughly €24.76 per share. This was the largest purchase by an insider in the last 3 months. This was Jakob's only on-market trade for the last 12 months. Annonce • Feb 13
Victrex plc, Annual General Meeting, Feb 12, 2021 Victrex plc, Annual General Meeting, Feb 12, 2021. Agenda: To receive the financial statements and the auditors' and Directors' reports for the year ended 30 September 2020; to approve the Directors' Remuneration Report; to declare a final dividend; to re-elect Director; to re-appoint PricewaterhouseCoopers LLP as auditor of the Company; to authorise the Audit Committee to determine the auditors' remuneration; to authorise political donations under the Companies Act 2006; to authorise the Directors' to allot shares pursuant to section 551 of the Companies Act 2006; to authorise the Directors to disapply the statutory rights of pre-emption to a further 5%; to purchase its own shares pursuant to section 701 of the Companies Act 2006; and to consider other matters. Is New 90 Day High Low • Jan 27
New 90-day high: €27.40 The company is up 32% from its price of €20.82 on 28 October 2020. The German market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 21% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €30.19 per share. Analyst Estimate Surprise Post Earnings • Jan 13
Revenue beats expectations Revenue exceeded analyst estimates by 0.3%. Over the next year, revenue is forecast to grow 2.3%, compared to a 3.9% growth forecast for the Chemicals industry in Germany. Reported Earnings • Jan 09
Full year 2020 earnings released: EPS UK£0.63 The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: UK£266.0m (down 9.5% from FY 2019). Net income: UK£54.2m (down 41% from FY 2019). Profit margin: 20% (down from 31% in FY 2019). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings. Analyst Estimate Surprise Post Earnings • Jan 09
Revenue beats expectations Revenue exceeded analyst estimates by 0.3%. Over the next year, revenue is forecast to grow 2.3%, compared to a 3.8% growth forecast for the Chemicals industry in Germany. Is New 90 Day High Low • Jan 04
New 90-day high: €26.18 The company is up 27% from its price of €20.54 on 06 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 15% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €29.36 per share. Is New 90 Day High Low • Dec 16
New 90-day high: €24.22 The company is up 11% from its price of €21.88 on 16 September 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €31.89 per share. Reported Earnings • Dec 11
Full year 2020 earnings released: EPS UK£0.63 The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: UK£266.0m (down 9.5% from FY 2019). Net income: UK£54.2m (down 41% from FY 2019). Profit margin: 20% (down from 31% in FY 2019). The decrease in margin was primarily driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings. Analyst Estimate Surprise Post Earnings • Dec 11
Revenue beats expectations Revenue exceeded analyst estimates by 0.3%. Over the next year, revenue is forecast to grow 3.4%, compared to a 4.1% growth forecast for the Chemicals industry in Germany. Valuation Update With 7 Day Price Move • Nov 13
Market bids up stock over the past week After last week's 15% share price gain to UK£23.12, the stock is trading at a trailing P/E ratio of 19.6x, up from the previous P/E ratio of 17x. This compares to an average P/E of 26x in the Chemicals industry in Germany. Total return to shareholders over the past three years is a loss of 4.7%. Is New 90 Day High Low • Nov 11
New 90-day high: €22.44 The company is up 7.0% from its price of €21.02 on 12 August 2020. The German market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €22.79 per share. Is New 90 Day High Low • Oct 14
New 90-day high: €22.34 The company is up 5.0% from its price of €21.32 on 16 July 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €22.42 per share. Annonce • Aug 15
Victrex plc to Report Fiscal Year 2020 Results on Dec 09, 2020 Victrex plc announced that they will report fiscal year 2020 results on Dec 09, 2020 Annonce • Jul 08
Victrex plc Do Not Provides Guidance for the Fiscal Year 2020 Victrex plc announced with an additional impact in current and forward order book from COVID-related headwinds, and with macro and end market uncertainty, as previously communicated, the company is unable to provide detailed guidance on 2020 full year expectations.